A randomized, placebo-controlled pilot phase-II clinical trial, Immuno-Modulation in Amyotrophic Lateral Sclerosis (IMODALS) was carried out to understand the safety and activity of ld-IL-2 in ALS patients. This evidence concerns the gene IL2 and amyotrophic lateral sclerosis.